Hoeki, hun info op website geeft al aan dat men een langzame salesgroei verwacht in de loop van komende jaren. En daar krijgt men weer (klein?) percentage van. Als Blrx er niets over meldt zal het voorlopig geen substantiele financiele impact hebben, anders is men verplicht als beursgenoteerd fonds er iets over te melden. Is ook niet een product dat (meer) past in hun core business, namelijk kanker medicijnen. Kortom, lijkt niet echt (koers) relevant product.
BL-5010
Indication: Benign skin lesions
Mode of action: Mummification and preservation of the lesions
Stage of development: Commercially launched
Patent status: International Patent Application covers the BL-5010P applicator, 20-year expiration in 2033
BL-5010 Overview
BL-5010 is a customized, proprietary pen-like applicator containing a novel, acidic, aqueous solution for the non-surgical removal of skin lesions. In December 2014, BioLineRx entered into an exclusive out-licensing arrangement with a subsidiary of Perrigo Company plc, or Perrigo, for the rights to BL-5010 for over-the-counter, or OTC, indications in the territory of Europe, Australia and additional selected countries. In March 2016, Perrigo received CE Mark approval for BL-5010 as a novel OTC treatment for the non-surgical removal of warts. The commercial launch of this first OTC indication (warts/verrucas) commenced in Europe in the second quarter of 2016 and sales are expected to slowly ramp up over the next 2-3 years.
BL-5010 was invented by Prof. Pinchas Burstein and is being developed by BioLineRx Ltd. under a worldwide exclusive license from Innovative Pharmaceutical Concepts (IPC) Inc.